HC Wainwright restated their buy rating on shares of Ocuphire Pharma (NASDAQ:OCUP – Free Report) in a research note released on Monday morning, Benzinga reports. The brokerage currently has a $20.00 target price on the stock. HC Wainwright also issued estimates for Ocuphire Pharma’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at ($0.29) […]